Royalty Pharma plc operates in the biopharmaceutical industry. More Details
Undervalued with mediocre balance sheet.
Share Price & News
How has Royalty Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: Insufficient data to determine RPRX's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how RPRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RPRX performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Royalty Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StAre Investors Undervaluing Royalty Pharma plc (NASDAQ:RPRX) By 40%?
1 month ago | Simply Wall StShould We Be Delighted With Royalty Pharma plc's (NASDAQ:RPRX) ROE Of 28%?
1 month ago | Simply Wall StHere's What Royalty Pharma plc's (NASDAQ:RPRX) Shareholder Ownership Structure Looks Like
Is Royalty Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RPRX ($42.97) is trading below our estimate of fair value ($68.32)
Significantly Below Fair Value: RPRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RPRX is good value based on its PE Ratio (9.1x) compared to the US Pharmaceuticals industry average (21.1x).
PE vs Market: RPRX is good value based on its PE Ratio (9.1x) compared to the US market (19.4x).
Price to Earnings Growth Ratio
PEG Ratio: RPRX is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: RPRX is good value based on its PB Ratio (3.6x) compared to the US Pharmaceuticals industry average (3.7x).
How is Royalty Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPRX's forecast earnings growth (8.6% per year) is above the savings rate (2.2%).
Earnings vs Market: RPRX's earnings (8.6% per year) are forecast to grow slower than the US market (21.9% per year).
High Growth Earnings: RPRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: RPRX's revenue (7.3% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: RPRX's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (29.8%)
How has Royalty Pharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: RPRX has high quality earnings.
Growing Profit Margin: RPRX's current net profit margins (86.9%) are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RPRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: RPRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RPRX had negative earnings growth (-17.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.8%).
Return on Equity
High ROE: RPRX's Return on Equity (28.4%) is considered high.
How is Royalty Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: RPRX's short term assets ($2.8B) exceed its short term liabilities ($270.0M).
Long Term Liabilities: RPRX's short term assets ($2.8B) do not cover its long term liabilities ($5.9B).
Debt to Equity History and Analysis
Debt Level: RPRX's debt to equity ratio (59.3%) is considered high.
Reducing Debt: Insufficient data to determine if RPRX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: RPRX's debt is well covered by operating cash flow (33.5%).
Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (19.6x coverage).
What is Royalty Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RPRX's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.49%).
High Dividend: RPRX's dividend (1.4%) is low compared to the top 25% of dividend payers in the US market (4.1%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether RPRX's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if RPRX's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: RPRX's dividends in 3 years are forecast to be well covered by earnings (23.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Pablo Legorreta (56 yo)
Mr. Pablo Gerardo Legorreta serves as the Chief Executive Officer and Co-Founder at RP Management, LLC. He also serves as Chairman of the Board at Royalty Pharma plc and has been its Chief Executive Office...
|Vice Chairman & Executive VP||0.92yr||no data||0.018% |
|Independent Director||0.50yr||no data||0.39% |
|Director||0.50yr||no data||0.0039% |
|Independent Director||0.42yr||no data||0.0026% |
|Independent Director||0.50yr||no data||0.0092% |
|Independent Director||0.42yr||no data||0% |
|Independent Director||0.50yr||no data||0.0092% |
|Independent Director||0.50yr||no data||0.000040% |
|Director||0.50yr||no data||15.17% |
|Independent Director||0.50yr||no data||0% |
Experienced Board: RPRX's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: RPRX only recently listed within the past 12 months.
Royalty Pharma plc's company bio, employee growth, exchange listings and data sources
- Name: Royalty Pharma plc
- Ticker: RPRX
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.678b
- Shares outstanding: 388.13m
- Website: https://www.royaltypharma.com
- Royalty Pharma plc
- 110 East 59th Street
- Floor 33
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RPRX||NasdaqGS (Nasdaq Global Select)||Yes||Class A Ordinary Shares||US||USD||Jun 2020|
|RPRX N||BMV (Bolsa Mexicana de Valores)||Yes||Class A Ordinary Shares||MX||MXN||Jun 2020|
|RPD||MUN (Boerse Muenchen)||Yes||Class A Ordinary Shares||DE||EUR||Jun 2020|
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/05 00:38|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.